You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0293 Safety, Pharmacokinetics, Enzyme Activity, and Immunogenicity of RSLV-132, A Novel Rnase Fusion Protein Developed To Reduce RNA-Containing Immune Complexes in Systemic Lupus Erythematosus

Article metrics

Article menu
Download PDFPDF
Poster Presentations
SLE, Sjögren's and APS - treatment
THU0293 Safety, Pharmacokinetics, Enzyme Activity, and Immunogenicity of RSLV-132, A Novel Rnase Fusion Protein Developed To Reduce RNA-Containing Immune Complexes in Systemic Lupus Erythematosus

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016300
Aug 2016400
Sep 2016200
Oct 20161300
Nov 20161900
Dec 20161201
Jan 20171100
Feb 20171401
Mar 20172101
Apr 2017900
May 20171202
Jun 20171701
Jul 20172902
Aug 20171200
Sep 20171000
Oct 20171601
Nov 20174001
Dec 20171401
Jan 2018800
Feb 20181200
Mar 20181000
Apr 2018800
May 20182801
Jun 20181000
Jul 20182400
Aug 2018400
Sep 20181400
Oct 2018200
Nov 2018200
Jan 20191202
Feb 20191401
Mar 2019800
Apr 20191103
May 20191400
Jun 20191000
Jul 2019801
Aug 20191300
Sep 2019200
Oct 2019600
Nov 20191500
Dec 2019300
Feb 20202201
Mar 2020200
Apr 2020400
May 2020400
Jun 2020400
Jul 2020600
Aug 20203201
Sep 20202201
Oct 2020300
Nov 2020200
Dec 20201600
Jan 2021402
Feb 2021600
Apr 2021200
May 2021200
Oct 2021400
Nov 2021800
Dec 2021800
Jan 2022600
Feb 2022701
Mar 20222100
Apr 2022300
May 2022800
Jun 2022800
Jul 20223501
Aug 20223200
Sep 20221000
Oct 20222200
Nov 2022200
Dec 20222800
Jan 2023800
Feb 2023400
Mar 2023700
Apr 2023300
May 2023600
Jun 2023500
Jul 2023500
Aug 20231400
Sep 2023800
Oct 20231900
Dec 2023800
Jan 2024200
Feb 20241200
Mar 20241300
Total943026